Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation
In this diverse community-based cohort, Q4W dosing outcomes, including DoT and completion rate, were comparable to other real-world studies with Q2W dosing and the PACIFIC and PACIFIC-R trials.
Authors
- Raymond Liu (ORCID: https://orcid.org/0000-0002-4667-9632)
- L. H. Chen
- Mike Zhou Yang
- Lori C. Sakoda (ORCID: https://orcid.org/0000-0002-0900-5735)
- Daniel Simmons (ORCID: https://orcid.org/0000-0002-3861-621X)
- Reina Haque (ORCID: https://orcid.org/0000-0001-8563-3330)
- Kristin Hsieh (ORCID: https://orcid.org/0000-0003-4100-473X)
- Eric C. McGary
- Ion Cotarla (ORCID: https://orcid.org/0000-0002-8986-3616)
- Zheng Zhu
- J. Marie Suga
Institutions
- Kaiser Permanente (US)
- New York Proton Center (US)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (United States) (US)
- Kaiser Permanente Tysons Corner Medical Center (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1080/14796694.2025.2603465
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00